Analyst Activity BTIG Research Reiterates Buy on bluebird bio (NASDAQ:BLUE) – Market Exclusive

Posted: May 1, 2017 at 9:41 am

Analyst Activity BTIG Research Reiterates Buy on bluebird bio (NASDAQ:BLUE)
Market Exclusive
With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product ...

and more »

Read the original post:
Analyst Activity BTIG Research Reiterates Buy on bluebird bio (NASDAQ:BLUE) - Market Exclusive

Related Posts

Comments are closed.

Archives